Nilotinib for the Treatment of Chronic Myeloid Leukemia: An Evidence-Based Review

Core Evidence - New Zealand
doi 10.2147/ce.s6003
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Satisfaction With Information on Nilotinib Treatment in Chronic Myeloid Leukemia Patients

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2019English

Development of Myasthenia Gravis in a Patient With Chronic Myeloid Leukemia During Treatment With Nilotinib

Hematology Reports
Hematology
2014English

Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients With Chronic Myeloid Leukemia

Biological and Pharmaceutical Bulletin
MedicinePharmacologyPharmaceutical Science
2015English

A Review of Omacetaxine: A Chronic Myeloid Leukemia Treatment Resurrected

Oncology and Therapy
Oncology
2018English

Prognostic Value of Tumor Clones Early Reducation in Patients With Chronic Myeloid Leukemia on Nilotinib Treatment Who Failed Imatinib

Hematology & blood transfusion: interdepartamental collection
2016English

Budget Impact Analysis or Pharmacological Therapy of Chronic Myeloid Leukemia (Cml) With Nilotinib as the Second-Line Treatment in Russian Federation

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Pancreatic Enzyme Elevation in Chronic Myeloid Leukemia Patients Treated With Nilotinib After Imatinib Failure

Haematologica
Hematology
2009English

Considerations for Successful Treatment-Free Remission in Chronic Myeloid Leukemia

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy